RGC - Rasio cepet Regencell

Regencell Bioscience develops pharmaceuticals based on Eastern medicine, generating stable demand for chronic pathologies. However, the risk of failed trials and a dependence on investment threaten its survival. The GURU.Markets system provides monitoring of urgent liquidity, where the current mark equals 10.86. The business remains at a venture stage, and scaling is limited by a narrow niche and high research costs.

The full outsourcing model of Regencell Bioscience (RGC) minimizes inventory risks; therefore, this liquidity ratio excluding inventories objectively reflects the company's ability to meet its obligations using cash and accounts receivable. By ignoring illiquid stocks, the metric reveals the actual reserve of "liquid" cash, allowing investors to distinguish temporary operational fluctuations from systemic financial depletion and assess the issuer's overall solvency.